Drug industry boosts lobbying amid growing scrutiny of prices

Drug industry boosts lobbying amid growing scrutiny of prices
© Getty Images

The pharmaceutical industry’s top trade group increased its lobbying spending in 2015 amid intensifying scrutiny of drug prices. 

The Pharmaceutical Research and Manufacturers of America (PhRMA) spent $18.32 million on lobbying in 2015, up from $16.51 million in 2014, according to disclosure records. 

ADVERTISEMENT

Last year was the first year that PhRMA’s lobbying spending rose since 2009, according to data from the Center for Responsive Politics. 

The increase came in a year when drug companies faced outcry over rising prices. Martin Shkreli, the hedge fund manager who increased the price of a drug to treat life-threatening infections from $13.50 to $750 overnight, has become the poster boy for the issue. 

Congress subpoenaed Shkreli on Wednesday, and the Senate Aging Committee has opened a bipartisan investigation into the broader issue of price hikes for drugs with expired patents. 

PhRMA has done its best to distance itself from Shkreli, pointing out that his company, Turing Pharmaceuticals, is not a member of the organization. The group's CEO, Stephen Ubl, wrote last month that Turing and another company in the spotlight, Valeant Pharmaceuticals, are “essentially hedge funds masquerading as pharmaceutical companies,” in contrast to the focus on research and development by most of the industry.  

Still, the attention on drug prices is wider. 

More than 50 Democratic lawmakers wrote to the Obama administration earlier this month suggesting that it should consider using its power under a 1980 law to lift the exclusive rights awarded to drug companies if they are unfairly pricing their products. 

In December, the bipartisan duo of Sens. Ron WydenRonald (Ron) Lee WydenElection security advocates see strong ally in Harris OVERNIGHT ENERGY: Watchdog report raises new questions for top Interior lawyer | Senate Democrats ask Trump to withdraw controversial public lands nominee | Border wall water use threatens endangered species, environmentalists say Watchdog report raises new questions for top Interior lawyer MORE (D-Ore.) and Chuck GrassleyCharles (Chuck) Ernest GrassleyThe Hill's Morning Report - Presented by Facebook - The choice: Biden-Harris vs. Trump-Pence Trump grabs 'third rail' of politics with payroll tax pause On The Money: McConnell says it's time to restart coronavirus talks | New report finds majority of Americans support merger moratorium | Corporate bankruptcies on pace for 10-year high MORE (R-Iowa) took the drug company Gilead Sciences to task for charging $84,000 for a course of its hepatitis C drug, Sovaldi.  

Democratic presidential candidates Hillary ClintonHillary Diane Rodham ClintonThe Hill's Campaign Report: Biden, Harris make first public appearance as running mates Trump campaign spox rips GOP congressman over rejection of QAnon conspiracy Biden hits back after Trump's attacks on Harris MORE and Bernie SandersBernie SandersOcasio-Cortez's 2nd grade teacher tells her 'you've got this' ahead of DNC speech Trump and allies grapple with how to target Harris Chris Wallace: Kamala Harris 'not far to the left despite what Republicans are gonna try to say' MORE have been pounding drug companies on the campaign trail and calling for policy moves strongly opposed by PhRMA, such as allowing Medicare to negotiate drug prices or allowing imported drugs from Canada. 

Republicans still largely oppose those changes, so major policy action remains unlikely in Congress in 2016. 

The Obama administration, however, has been exploring the possibility of taking some actions on its own. 

The Department of Health and Human Services held a forum in November on drug prices, raising the possibility of new value-based payment models for Medicare and Medicaid that would pay for a drug based on how effective it is shown to be.  The administration has also taken steps to increase transparency, launching an online “dashboard” to show the price of certain high-cost drugs. 

While drug spending increased by 12.2 percent in 2014, PhRMA emphasized that spending on prescription drugs remained only around 10 percent of healthcare spending overall.